Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
papaveretum 15,4 mg + hyoscin 400 µg injektionsvæske, opløsning, ampul a 1 ml |
Is a |
papaveretum + hyoscinhydrobromid |
false |
Inferred relationship |
Some |
|
|
papaveretum 15,4 mg + hyoscin 400 µg injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Opium preparation |
false |
Inferred relationship |
Some |
|
|
papaveretum 15,4 mg + hyoscin 400 µg injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Papaveretum (substance) |
false |
Inferred relationship |
Some |
|
|
papaveretum 15,4 mg + hyoscin 400 µg injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Opium |
false |
Inferred relationship |
Some |
|
|
papaveretum 15,4 mg + hyoscin 400 µg injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Central nervous system agent (substance) |
false |
Inferred relationship |
Some |
|
|
papaveretum 15,4 mg + hyoscin 400 µg injektionsvæske, opløsning, ampul a 1 ml |
Has manufactured dose form |
injektionsvæske |
false |
Inferred relationship |
Some |
|
|
papaveretum 15,4 mg + hyoscin 400 µg injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Scopolamine hydrobromide (substance) |
false |
Inferred relationship |
Some |
|
|
papaveretum 15,4 mg + hyoscin 400 µg injektionsvæske, opløsning, ampul a 1 ml |
Is a |
Product containing scopolamine in parenteral dose form (medicinal product form) |
false |
Inferred relationship |
Some |
|
|
papaveretum 15,4 mg + hyoscin 400 µg injektionsvæske, opløsning, ampul a 1 ml |
Has manufactured dose form |
Solution for injection |
false |
Inferred relationship |
Some |
|
|